Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Ustekinumab may benefit Crohn’s patients when anti-TNF fails

By News team

Moderate-to-severe Crohn’s disease that has been unresponsive to anti-tumour necrosis factor treatment may respond to ustekinumab, according to research in The New England Journal of Medicine (2012;361:1519).

In a phase II study funded by Janssen, 526 patients were randomised to receive intravenous ustekinumab — currently licensed to treat severe plaque psoriasis — or placebo for induction therapy (0–8 weeks), then subcutaneous ustekinumab or placebo maintenance (8–36 weeks).

Patients who received 6mg/kg ustekinumab for induction had a better response rate at week 6 than those who received placebo (39.7 per cent versus 23.5 per cent; P=0.005). Furthermore, patients who showed an initial response to ustekinumab had significantly higher rates of response and remission with ustekinumab during maintenance therapy (secondary endpoints).

Citation: The Pharmaceutical Journal URI: 11109925

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Cartoon of gastrointestinal system (Wuka/

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.